Table 3. SVR₁₂ according to baseline patient characteristics and on-treatment HCV viral decline.

Characteristics	Patient (N = 273)
	Patient No.	SVR12 (%)	95% CI
Age, years
< 60	85	94.1	87.0–97.5
≥ 60	188	97.9	94.7–99.2
Sex
Female	146	96.6	92.2–98.5
Male	127	96.9	92.2–98.8
Treatment experience
Naïve	182	96.7	93.0–98.5
Experienced	91	96.7	90.8–98.9
HBV coinfection
Absent	264	96.6	93.7–98.2
Present	9	100	70.1–100
HIV coinfection
Absent	260	96.5	93.6–98.2
Present	13	100	77.2–100
Prior HCC history
Absent	216	96.8	93.5–98.4
Present	57	96.5	88.1–99.0
Liver transplantation
No	247	96.4	93.2–98.1
Yes	26	100	87.1–100
Renal transplantation
No	260	96.5	93.6–98.2
Yes	13	100	77.2–100
Treatment duration, week
8	5	100	56.6–100
12	265	96.6	93.7–98.2
24	3	100	43.9–100
RBV usage
No	185	97.3	93.8–98.8
Yes	88	95.5	88.9–98.2
eGFR, mL/min/1.73m2
< 60	52	98.1	89.9–99.7
≥ 60	221	96.4	93.0–98.2
HCV RNA, IU/mL
< 6,000,000	225	96.4	93.1–98.2
≥ 6,000,000	48	97.9	89.1–99.6
HCV genotype
1a	21	90.5	71.1–97.4
1b	242	97.9	95.3–99.1
1	10	80.0	49.0–94.3
Cirrhosis
Absent	138	97.8	93.8–99.3
Present	135	95.6	90.7–98.0
Child-Pugh A	109	97.3	92.2–99.1
Child-Pugh B and C	26	88.5	71.0–96.0
Week 4 HCV RNA < LLOD*
No	54	94.4	84.9–98.1
Yes	218	97.7	94.8–99.0

NA: not assessed.

* One patient who expired at treatment week 3 did not have week 4 HCV RNA data.